+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Successful treatment of non-Hodgkin's lymphoma with rituximab and dose-adjusted CHOP therapy in a patient with concomitant end-stage renal disease requiring haemodialysis



Successful treatment of non-Hodgkin's lymphoma with rituximab and dose-adjusted CHOP therapy in a patient with concomitant end-stage renal disease requiring haemodialysis



Ndt Plus 4(3): 186-189



Although malignancy is a fatal complication of end-stage renal disease (ESRD) requiring haemodialysis, successful treatment of haematological malignancies has been rarely reported. We describe the case of a 64-year-old man who presented with non-Hodgkin's lymphoma (NHL; clinical stage, IVB) concomitant with ESRD. Before chemotherapy, haemodialysis was initiated, and one course of dose-adjusted CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) therapy followed by eight courses of rituximab therapy were administered according to the performance status and degree of organ dysfunction. Consequently, the patient was disease free for 27 months. Thus, rituximab plus CHOP combination therapy was effective for NHL concomitant with ESRD.

(PDF emailed within 0-6 h: $19.90)

Accession: 036104800

Download citation: RISBibTeXText

PMID: 25984153

DOI: 10.1093/ndtplus/sfr007


Related references

Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requiring haemodialysis. Cen Case Reports 3(1): 24-29, 2014

Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requir. 2013

Successful Treatment of Diffuse Large B-Cell Non-Hodgkin Lymphoma with Modified CHOP (Cyclophosphamide/Doxorubicin/Vincristine/ Prednisone) Chemotherapy and Rituximab in a Patient with Nijmegen Syndrome. Clinical Lymphoma & Myeloma 7(9): 590-593, 2007

Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome. Clinical Lymphoma and Myeloma 7(9): 590-593, 2008

Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab. Internal Medicine 43(2): 131-134, 2004

Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab. Leukemia and Lymphoma 46(11): 1613-1617, 2005

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 18(12): 781-787, 2018

Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leukemia and Lymphoma 47(7): 1306-1314, 2006

Treatment of a patient with chronic renal failure with rituximab for a follicular lymphoma: Safe and successful option of rituximab therapy. European Journal of Haematology 71(2): 128-129, 2003

Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. Rheumatology International 28(2): 179-183, 2007

The successful treatment of primary cardiac lymphoma with a dose-dense schedule of rituximab plus CHOP. Annals of Oncology 17(1): 176-177, 2005

Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy Regimen. Cureus 11(1): E3814, 2019

Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. Pediatric Blood and Cancer 50(4): 883-885, 2007

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 16(2): 76-81, 2016

Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. Clinical Advances in Hematology and Oncology 3(7): 544-546, 2005